MISSISSAUGA, Ontario, Feb. 22, 2011 /PRNewswire/ — CardioGenics
Holdings Inc. (OTC Bulletin Board:
CGNH) announced today that it has been notified by the Canadian
Intellectual Property Office that its patent application for the
“core technology” utilized in its ultra-sensitive point-of-care
immuno-analyzer, the QL Care™ Analyzer, has been granted.
Patents covering the “core technology” have now been issued in
Canada, the European Union and Japan. A patent application for the
“core technology” is currently pending in the U.S. before the
United States Patent & Trademark Office (USPTO).
Yahia Gawad, MD, Chief Executive Officer of CardioGenics
Holdings Inc. said, “We are very pleased that the patent offices of
Canada, the European Union and Japan have acknowledged the unique
nature of the ‘core technology’ upon which our QL Care™
Analyzer is based.”
“The granting of these patents in these major commercial markets
further enhances the value of CardioGenics’ intellectual property
portfolio and we now look forward to a similar disposition of our
patent application for the ‘core technology’ from the USPTO,”
continued Dr. Gawad.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops
ultra-sensitive analyzers and other products targeting the
immunoassay segment of the Point-Of-Care IVD testing market. It has
developed the QL Care™ Analyzer, a proprietary and
ultra-sensitive Point-Of-Care immuno-analyzer, which will run a
number of diagnostic tests under development, the first of which
will be a series of cardiovascular diagnostic tests. As part of its
core proprietary technology, the Company has also developed a
proprietary method for silver coating paramagnetic microspheres (a
fundamental platform component of immunoassay equipment), which
improve instrument sensitivity to light. The Company’s
‘/>”/>
SOURCE
